Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
10.69
-0.32 (-2.91%)
At close: Oct 13, 2025, 4:00 PM EDT
10.84
+0.15 (1.40%)
After-hours: Oct 13, 2025, 5:11 PM EDT
Zevra Therapeutics Revenue
Zevra Therapeutics had revenue of $25.88M in the quarter ending June 30, 2025, with 481.73% growth. This brings the company's revenue in the last twelve months to $62.02M, up 161.81% year-over-year. In the year 2024, Zevra Therapeutics had annual revenue of $23.61M, down -14.02%.
Revenue (ttm)
$62.02M
Revenue Growth
+161.81%
P/S Ratio
9.33
Revenue / Employee
$1,051,186
Employees
59
Market Cap
600.08M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 23.61M | -3.85M | -14.02% |
| Dec 31, 2023 | 27.46M | 17.30M | 170.26% |
| Dec 31, 2022 | 10.16M | -18.49M | -64.53% |
| Dec 31, 2021 | 28.65M | 15.36M | 115.61% |
| Dec 31, 2020 | 13.29M | 449.00K | 3.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ZVRA News
- 6 days ago - Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 25 days ago - Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyrate) - GlobeNewsWire
- 5 weeks ago - Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM) - GlobeNewsWire
- 6 weeks ago - Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM) - GlobeNewsWire
- 6 weeks ago - Zevra Therapeutics to Participate at Upcoming Investor Conferences in September - GlobeNewsWire
- 2 months ago - Zevra Therapeutics, Inc. (ZVRA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Zevra Reports Second Quarter 2025 Financial Results and Corporate Update - GlobeNewsWire
- 2 months ago - Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call - GlobeNewsWire